

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE <b>43</b> Years	3. SEX <b>Female</b>	3a. WEIGHT <b>109.30</b> kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY  <input type="checkbox"/> OTHER	
		Day	Month	Year			Day	Month	Year			
										<b>07</b>	<b>APR</b>	<b>2025</b>

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)  
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)  
 Dizziness [Dizziness]  
 Nausea [Nausea]  
 dysgeusia [Dysgeusia]  
 dizziness [Dizziness]

Case Description: \*\*\*This is an auto generated narrative\*\*\*

Study ID: 828652-My Healthy Journey

Study description: Trial title: This is a 40 weeks digital patient (Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) 1.8 mg, qd	16. ROUTE(S) OF ADMINISTRATION #1 ) Subcutaneous	
17. INDICATION(S) FOR USE #1 ) Obesity (Obesity)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1 ) 07-APR-2025 / Ongoing	19. THERAPY DURATION #1 ) Unknown	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)																	
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) <table border="1"> <thead> <tr> <th>From/To Dates</th> <th>Type of History / Notes</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>Unknown to Ongoing</td> <td>Current Condition</td> <td>Obesity (Obesity)</td> </tr> <tr> <td></td> <td>Duration was not reported</td> <td></td> </tr> <tr> <td>Unknown to Ongoing</td> <td>Current Condition</td> <td>Insulin resistance (Insulin resistance)</td> </tr> <tr> <td></td> <td>Duration not reported.</td> <td></td> </tr> </tbody> </table>			From/To Dates	Type of History / Notes	Description	Unknown to Ongoing	Current Condition	Obesity (Obesity)		Duration was not reported		Unknown to Ongoing	Current Condition	Insulin resistance (Insulin resistance)		Duration not reported.	
From/To Dates	Type of History / Notes	Description															
Unknown to Ongoing	Current Condition	Obesity (Obesity)															
	Duration was not reported																
Unknown to Ongoing	Current Condition	Insulin resistance (Insulin resistance)															
	Duration not reported.																

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No
	24b. MFR CONTROL NO. <b>1412891</b>	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER <b>24-APR-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>23-JUN-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 165 cm.

Patient's weight: 109.3 kg.

Patient's BMI: 40.14692380.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Dizziness(Dizziness)" beginning on 07-APR-2025 , "Nausea(Nausea)" with an unspecified onset date , "dysgeusia(Dysgeusia)" with an unspecified onset date , "dizziness(Dizziness)" with an unspecified onset date and concerned a 43 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from 07-APR-2025 and ongoing for "Obesity",

Dosage Regimens:

Saxenda: 07-APR-2025 to Not Reported (Dosage Regimen Ongoing);

Current Condition: Obesity, Insulin resistance

Historical Condition: bulimia

Procedure: Sleeve gastrectomy.

Batch Numbers:

Saxenda: ASKU;

Action taken to Saxenda was reported as No Change.

The outcome for the event "Dizziness(Dizziness)" was Recovered.

The outcome for the event "Nausea(Nausea)" was Recovered.

The outcome for the event "dysgeusia(Dysgeusia)" was Recovered.

The outcome for the event "dizziness(Dizziness)" was Recovered.

Reporter's causality (Saxenda) -

Dizziness(Dizziness) : Unknown

Nausea(Nausea) : Unknown

dysgeusia(Dysgeusia) : Unknown

dizziness(Dizziness) : Unknown

Company's causality (Saxenda) -

Dizziness(Dizziness) : Possible

Nausea(Nausea) : Possible

dysgeusia(Dysgeusia) : Possible

dizziness(Dizziness) : Possible

Reporter Comment: Treatment Received: Reduce the 6 meals to 3-4 meals

**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Procedure Duration not reported.	Sleeve gastrectomy (Sleeve gastrectomy);
Unknown	Historical Condition in adolescence	Bulimia (Bulimia nervosa);